Eli Lilly and Co has successfully launched a substantial $6.5 billion notes offering, as detailed in their Free Writing Prospectus filed with the SEC under Rule 433. The offering, dated February 7, 2024, includes a series of notes with varying maturities: 2027, 2029, 2034, 2054, and 2064, each with a fixed annual coupon rate ranging from 4.500% to 5.100%. The trade date for the notes was February 7, 2024, with a settlement date of February 9, 2024. The notes received high credit ratings from Moody's (A1) and S&P (A+), both with stable outlooks. The joint book-running managers for the transaction included BofA Securities, Inc., Barclays Capital Inc., and Citigroup Global Markets Inc., among others. The offering was priced close to the principal amount, with yields to maturity slightly exceeding the coupon rates. The notes are redeemable at par after a specified date, with make-whole call provisions in place before that. The registration statement for the offering, No. 333-262943, is available on the SEC's website, and the prospectus can be obtained from the underwriters.

Eli Lilly and Co has successfully launched a substantial $6.5 billion notes offering, as detailed in their Free Writing Prospectus filed with the SEC under Rule 433. The offering, dated February 7, 2024, includes a series of notes with varying maturities: 2027, 2029, 2034, 2054, and 2064, each with a fixed annual coupon rate ranging from 4.500% to 5.100%. The trade date for the notes was February 7, 2024, with a settlement date of February 9, 2024. The notes received high credit ratings from Moody's (A1) and S&P (A+), both with stable outlooks. The joint book-running managers for the transaction included BofA Securities, Inc., Barclays Capital Inc., and Citigroup Global Markets Inc., among others. The offering was priced close to the principal amount, with yields to maturity slightly exceeding the coupon rates. The notes are redeemable at par after a specified date, with make-whole call provisions in place before that. The registration statement for the offering, No. 333-262943, is available on the SEC's website, and the prospectus can be obtained from the underwriters.